Reactive arthritis medical therapy

Revision as of 17:19, 11 April 2018 by Akshun Kalia (talk | contribs)
Jump to navigation Jump to search

Reactive arthritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Reactive arthritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Reactive arthritis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Reactive arthritis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Reactive arthritis medical therapy

CDC on Reactive arthritis medical therapy

Reactive arthritis medical therapy in the news

Blogs onReactive arthritis medical therapy

Directions to Hospitals Treating Reactive arthritis

Risk calculators and risk factors forReactive arthritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

  • Reactive arthritis is generally seen with preceeding GI or GU infections. Antibiotics may be given if there is an ongoing infection, but generally patients of reactive arthritis do not require antibiotic therapy. Recent studies have shown that antibiotic therapy does not alter the course of disease and their role in reactive arthritis is not completely established.[1][2]
  • Arthritis (mono or oligoarthritis) is most common initial symptom and therefore primary medical therapy is aimed at alleviating arthritis.
  • Pharmacologic medical therapies for reactive arthritis include symptomatic control starting initially with NSAIDs.<refD van der Heijde, HSB Baraf, C Ramos-Remus, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study Arthritis Rheum, 52 (2005), pp. 1205–1215</ref>
  • As the disease progresses or in case of no response, further management includes intra-articular and systemic steroids, DMARDs and finally TNF inhibitors.
    • 1.1 NSAIDs such as the COX-2 inhibitors
      • Preferred regimen (1): Naproxen 500 mg PO q8-12h daily.
      • Preferred regimen (2): Diclofenac 50 mg PO q8h daily.
      • Preferred regimen (3): Indomethacin 50 mg PO q6-8h daily.
      Note(1):NSAIDs are usually given for a duration of two weeks.
      Note(2):NSAIDs are contraindicated in patients with GI bleeding, heart disease and renal disease.
    • 2.1 Steroid therapy Patients with inadequate response to NSAID are given intra-articular steroids initially and in case of no response are given systemic systemic steroids .
      • Preferred regimen (1): Triamcinolone acetonide 40 mg given as intra-articular injection.
      • Preferred regimen (2): Methylprednisolone acetate 20-60 mg as intra-articular injection.
      Note(1):Intra-articular injections are given every 1- 5 weeks depending upon response.
      Note(2):Most common side effects of intra-articular steroids include osteonecrosis and acute synovitis.
      • Alternative regimen (1): Patients unresponsive to NSAIDs and intra-articular steroids are advised systemic glucocorticoids such as prednisone 20 mg PO q24 daily.
      Note(1):Glucocorticoids should be started with the minimum dose and gradually increased if desired effect is not achieved.
    • 3.1 Steroid therapyPatients unresponsive to NSAIDs and steroids are advised DMARDs.<re>Treatment of juvenile spondyloarthritis and reactive arthritis with sulfasalazine Monatsschr. Kinderheilkd, 140 (1992), pp. 658–660 </ref>
      • Preferred regimen (1): Sulfasalazine 500 mg PO q24 daily, if unresponsive dose can be increased to 1000-3000 mg BID daily.
      • Preferred regimen (2): Methotrexate 15 to 25 mg PO one day weekly.
      Note(1):The duration of therapy with DMARDs is four months for sulfasalazine.
      Note(2):For methotrexate the duration of therapy is three months.
    • 4.1 Tumor necrosis factor (TNF) inhibitorsPatients unresponsive to above therapy are advised TNF inhibitors.[3]
      • Preferred regimen (1): Etanercept 50 mg/week given as subcutaneous injection.
      • Preferred regimen (2): Infliximab 3 to 5 mg/kg administered intravenously on weeks zero, two, and six and then every eight weeks.
      Note(1):The duration of treatment is 3 months.
      Note(2):If the patients does not respond to one TNF another TNF agent may be given
      Note(3):Treatment is discontinued when patient goes into remission for at least three months.
  • For treatment of ocular symptoms such as conjunctivitis, please click here
  • For treatment of urethritis please click here
  • Skin and mucous membrane lesions are generally self limited and therefore do not require further intervention.

References

  1. Barber CE, Kim J, Inman RD, Esdaile JM, James MT (June 2013). "Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis". J. Rheumatol. 40 (6): 916–28. doi:10.3899/jrheum.121192. PMID 23588936.
  2. C.E. Barber, J. Kim, R.D. Inman, et al. Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis J. Rheumatol., 40 (2013), pp. 916–928
  3. K.S. Oili, H. Niinisalo, T. Korpilähde, J. Virolainen Treatment of reactive arthritis with infliximab Scand. J. Rheumatol., 32 (2003), pp. 122–124


Template:WikiDoc Sources